Risk Management of Shortage of Drug Prices

The National Health Insurance Administration issued the "Operational Guidelines for Risk Management of Shortage Drug Prices" (Yibao Banfa [2024] No. 30), which was released in December 2024, and the main contents include: clarifying the scope of application: strictly comparing the "two lists" and the specific varieties required by the leading departments of the linkage mechanism for emergency treatment, and insisting on giving priority to "ensuring supply". Adhere to market pricing: Adhere to market pricing for shortages and drug prices, and enterprises, as the first responsible persons for drug prices, can independently adjust prices according to reasonable factors such as cost changes. Combination of prevention and disposal: Adhere to a fair, reasonable, transparent and balanced price orientation, strengthen information disclosure when accepting and listing on the Internet, study and judge potential price risks, and adopt differentiated measures for direct listing. Responsible for compaction of the first increase: The first province to accept the price increase and the network is responsible for taking the lead in data review, price and cost investigation, and supervision and rectification, and actively shares the information and risk disposal results with other provinces.